Serveur d'exploration Tocilizumab - Analysis (2020)

Index « Titre (en) » - entrée « therapies »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
therapie < therapies < therapy  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 14.
Ident.Authors (with country if any)Title
000003 (2020) Charlotte Girard-Guyonvarc'H ; Michele Iudici[Targeted therapies for connective tissue diseases and vasculitis].
000038 (2020) Maria C. Cid [Espagne] ; Roberto Ríos-Garcés [Espagne] ; Nekane Terrades-García [Espagne] ; Georgina Espígol-Frigolé [Espagne]Treatment of giant-cell arteritis: from broad spectrum immunosuppressive agents to targeted therapies.
000047 (2020) María Martín-L Pez [Espagne] ; Eliseo Albert [Espagne] ; Mario Fernández-Ruiz [Espagne] ; Isidoro González-Álvaro [Espagne] ; Esther Rodríguez [Espagne] ; José M. Aguado [Espagne] ; David Navarro [Espagne] ; José L. Pablos [Espagne]Torque teno virus viremia in patients with chronic arthritis: Influence of biologic therapies.
000091 (2020) Guillaume Decarriere [France] ; Thomas Barnetche [France] ; Bernard Combe [France] ; Cécile Gaujoux-Viala [France] ; Cédric Lukas [France] ; Jacques Morel [France] ; Claire Daien [France]The most appropriate conventional DMARD to combine with different advanced therapies in rheumatoid arthritis: a systematic literature review with meta-analysis.
000113 (2020) José M. Carballido [Suisse] ; Camille Regairaz [Suisse] ; Celine Rauld [Suisse] ; Layla Raad [Suisse] ; Damien Picard [Suisse] ; Michael Kammüller [Suisse]The Emerging Jamboree of Transformative Therapies for Autoimmune Diseases
000173 (2020) Siddappa N. Byrareddy [États-Unis] ; Mahesh Mohan [États-Unis]SARS-CoV2 induced respiratory distress: Can Cannabinoids be added to anti-viral therapies to reduce lung inflammation?
000183 (2020) Ibai Los-Arcos [Espagne] ; Juan Aguilar-Company [Espagne] ; Isabel Ruiz-Camps [Espagne]Risk of infection associated with new therapies for lymphoproliferative syndromes.
000194 (2020) Alimuddin Zumla [Royaume-Uni] ; David S. Hui [République populaire de Chine] ; Esam I. Azhar [Arabie saoudite] ; Ziad A. Memish [Arabie saoudite] ; Markus Maeurer [Portugal, Allemagne]Reducing mortality from 2019-nCoV: host-directed therapies should be an option
000304 (2020) Claudio Ronco [Italie] ; Thiago Reis [Italie, Brésil]Kidney involvement in COVID-19 and rationale for extracorporeal therapies
000338 (2020) Ivan Arias De La Rosa [Espagne] ; Carlos Perez-Sanchez [Royaume-Uni] ; Patricia Ruiz-Limon [Espagne] ; Alejandra Pati O-Trives [Espagne] ; Carmen Torres-Granados [Espagne] ; Yolanda Jimenez-Gomez [Espagne] ; Maria Del Carmen Abalos-Aguilera [Espagne] ; Irene Cecchi [Italie] ; Rafaela Ortega [Espagne] ; Miguel Angel Caracuel [Espagne] ; Jerusalem Calvo-Gutierrez [Espagne] ; Alejandro Escudero-Contreras [Espagne] ; Eduardo Collantes-Estevez [Espagne] ; Chary Lopez-Pedrera [Espagne] ; Nuria Barbarroja [Oman]Impaired microRNA processing in neutrophils from rheumatoid arthritis patients confers their pathogenic profile. Modulation by biological therapies.
000434 (2020) Rahime Koç [Turquie] ; Hafize Emine Sönmez [Turquie] ; Mustafa Çakan [Turquie] ; Erife Gül Karada [Turquie] ; Ay E Tanatar [Turquie] ; Figen Çakmak [Turquie] ; Nuray Aktay Ayaz [Turquie]Drug reactions in children with rheumatic diseases receiving parenteral therapies: 9 years' experience of a tertiary pediatric rheumatology center.
000583 (2020) Gavin GiovannoniAnti-CD20 immunosuppressive disease-modifying therapies and COVID-19
000584 (2020) Itay Lotan [États-Unis] ; Richard Mcgowan [États-Unis] ; Michael Levy [États-Unis]Anti- IL-6 therapies for neuromyelitis optica spectrum disorders: A systematic review of safety and efficacy.
000618 (2019) Maurizio Benucci [Italie] ; Valentina Grossi [Italie] ; Mariangela Manfredi [Italie] ; Arianna Damiani [Italie] ; Maria Infantino [Italie] ; Paolo Moscato [Italie] ; Luigi Cinquanta [Italie] ; Elisa Gremese [Italie] ; Barbara Tolusso [Italie] ; Luca Petricca [Italie] ; Anna Laura Fedele [Italie] ; Stefano Alivernini [Italie] ; Fabiola Atzeni [Italie] ; Giovanni Minisola [Italie] ; Roberto Verna [Italie]Laboratory Monitoring of Biological Therapies in Rheumatology: The Role of Immunogenicity

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/2020/Analysis
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i -k "therapies" 
HfdIndexSelect -h $EXPLOR_AREA/Data/2020/Analysis/Title.i  \
                -Sk "therapies" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/2020/Analysis/biblio.hfd 

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    2020
   |étape=   Analysis
   |type=    indexItem
   |index=    Title.i
   |clé=    therapies
}}

Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021